Shandong Pharmaceutical Glass Co Ltd (600529) — Cash Flow-to-Debt Ratio
Shandong Pharmaceutical Glass Co Ltd (600529) has a Cash Flow-to-Debt Ratio of 0.02x as of December 2025, meaning its operating cash flow of CN¥41.46 Million could theoretically repay 0% of its total liabilities (CN¥1.75 Billion) in one year. See Shandong Pharmaceutical Glass Co Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Shandong Pharmaceutical Glass Co Ltd Cash Flow-to-Debt Ratio (2001–2025)
Historical debt coverage capacity for Shandong Pharmaceutical Glass Co Ltd across 25 annual periods. Also explore how fast is Shandong Pharmaceutical Glass Co Ltd growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Shandong Pharmaceutical Glass Co Ltd (2001–2025)
Year-by-year debt coverage analysis for Shandong Pharmaceutical Glass Co Ltd. For market capitalisation and broader financial context, see market value of Shandong Pharmaceutical Glass Co Ltd.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.33x | CN¥576.92 Million | CN¥1.75 Billion | ▼ -39.6% |
| 2024 | 0.55x | CN¥1.17 Billion | CN¥2.13 Billion | ▼ -7.0% |
| 2023 | 0.59x | CN¥1.05 Billion | CN¥1.78 Billion | ▲ +324.1% |
| 2022 | 0.14x | CN¥252.44 Million | CN¥1.82 Billion | ▼ -67.9% |
| 2021 | 0.43x | CN¥750.44 Million | CN¥1.74 Billion | ▲ +4.1% |
| 2020 | 0.41x | CN¥566.01 Million | CN¥1.37 Billion | ▼ -9.9% |
| 2019 | 0.46x | CN¥599.05 Million | CN¥1.30 Billion | ▲ +8.4% |
| 2018 | 0.42x | CN¥465.77 Million | CN¥1.10 Billion | ▼ -4.3% |
| 2017 | 0.44x | CN¥411.96 Million | CN¥929.84 Million | ▼ -24.7% |
| 2016 | 0.59x | CN¥506.53 Million | CN¥860.62 Million | ▲ +11.1% |
| 2015 | 0.53x | CN¥389.63 Million | CN¥735.61 Million | ▲ +37.6% |
| 2014 | 0.38x | CN¥266.63 Million | CN¥692.56 Million | ▼ -3.2% |
| 2013 | 0.40x | CN¥268.60 Million | CN¥675.48 Million | ▲ +836.7% |
| 2012 | 0.04x | CN¥28.52 Million | CN¥671.80 Million | ▼ -90.0% |
| 2011 | 0.43x | CN¥274.63 Million | CN¥644.80 Million | ▲ +52.8% |
| 2010 | 0.28x | CN¥217.01 Million | CN¥778.34 Million | ▼ -30.3% |
| 2009 | 0.40x | CN¥249.27 Million | CN¥623.51 Million | ▲ +132.9% |
| 2008 | 0.17x | CN¥91.76 Million | CN¥534.52 Million | ▼ -21.0% |
| 2007 | 0.22x | CN¥122.63 Million | CN¥564.66 Million | ▲ +95.4% |
| 2006 | 0.11x | CN¥78.47 Million | CN¥705.86 Million | ▲ +42.3% |
| 2005 | 0.08x | CN¥44.09 Million | CN¥564.27 Million | ▲ +1018.5% |
| 2004 | -0.01x | CN¥-3.70 Million | CN¥434.85 Million | ▼ -104.5% |
| 2003 | 0.19x | CN¥59.35 Million | CN¥310.80 Million | ▼ -48.7% |
| 2002 | 0.37x | CN¥109.26 Million | CN¥293.28 Million | ▲ +216.4% |
| 2001 | 0.12x | CN¥28.60 Million | CN¥242.90 Million | — |